MMJ Phytotech Ltd., of Perth Australia, said its wholly owned, Israeli-based subsidiary Phytotech Therapeutics Ltd. will start a phase II trial testing PTL101 capsules in treating intractable epilepsy in children. Planning for an additional phase II study to treat spasticity related symptoms of multiple sclerosis patients using PTL201 is well advanced, the company said. The capsules contain organically derived, highly purified cannabidiol and are using a formulation developed through the company's Gelpell technology.